KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Pacific Biosciences Of California (PACB) Accumulated Depreciation & Amortization (2016 - 2025)

Pacific Biosciences Of California (PACB) has 14 years of Accumulated Depreciation & Amortization data on record, last reported at $92.5 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 12.84% year-over-year to $92.5 million; the TTM value through Dec 2025 reached $92.5 million, up 12.84%, while the annual FY2025 figure was $92.5 million, 12.84% up from the prior year.
  • Accumulated Depreciation & Amortization reached $92.5 million in Q4 2025 per PACB's latest filing, up from $81.9 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $92.5 million in Q4 2025 and bottomed at $56.3 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $74.1 million, with a median of $74.8 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: increased 15.46% in 2022, then increased 9.56% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $56.3 million in 2021, then grew by 15.46% to $65.0 million in 2022, then grew by 15.09% to $74.8 million in 2023, then increased by 9.56% to $81.9 million in 2024, then rose by 12.84% to $92.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $92.5 million in Q4 2025, $81.9 million in Q4 2024, and $74.8 million in Q4 2023.